echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Veru's share price surges over 180% after the success of the new crown oral drug phase III

    Veru's share price surges over 180% after the success of the new crown oral drug phase III

    • Last Update: 2022-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    TextSunshine

    On April 11, Veru announced that sabizabulin (bisindole) reduced the relative risk of death by 55% in moderate-to-severe COVID-19 hospitalized patients


    Affected by this news, Veru's shares rose 182%


    Sabizabulin is an oral tubulin inhibitor developed by Veru, which blocks the intracellular transport of the new coronavirus along microtubules by inhibiting tubulin


    This is a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of sabizabulin in patients with moderate-to-severe COVID-19 at risk of acute respiratory distress syndrome (ARDS) and death


    This release is an interim analysis of the first 150 patients enrolled


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.